NewLimit, a startup that aims to increase how long people can live a healthy life by genetically programming their cells, has raised a $130 million Series B led by Kleiner Perkins.
New investors Nat Friedman, Daniel Gross, and Khosla Ventures also invested, as did returning backers Founders Fund, Dimension Capital, Elad Gil, Garry Tan, Patrick Collison, and others. The fundraise comes two years after the company raised a $40 million Series A.
Founded over four years ago by Coinbase CEO Brian Armstrong (pictured above), former GV partner Blake Byers, and stem cell professor Jacob Kimmel, NewLimit claims it has made significant progress toward developing treatments that can restore youthful characteristics to aged cells.
Byers told TechCrunch the company has discovered three prototype medicines that reprogram liver cells. NewLimit’s lab experiments, he said, demonstrate this rejuvenation can restore the cells’ ability to process fat and alcohol.
The company measures its progress by contrasting how cells from a younger individual and an older person respond to the substances. An older liver cell that has gone through NewLimit’s epigenetic reprogramming behaves more like a younger cell, Byers said.
Promising early results notwithstanding, NewLimit is still a few years away from starting human trials.
In the meantime, the company wants to continue developing new anti-aging medicine using an AI model and then testing the most promising of these machine-generated drugs in its laboratory. “What the AI model allows us to do is run all those experiments in simulation and then only follow up on the most promising subset,” Byers said, adding that the data points from the experiment are then used to retrain the AI model in a process known as “lab in a loop.”
Techcrunch event
Exhibit at TechCrunch Sessions: AI
Secure your spot at TC Sessions: AI and show 1,200+ decision-makers what you’ve built — without the big spend. Available through May 9 or while tables last.
Exhibit at TechCrunch Sessions: AI
Secure your spot at TC Sessions: AI and show 1,200+ decision-makers what you’ve built — without the big spend. Available through May 9 or while tables last.
Berkeley, CA
|
June 5
BOOK NOW
Other noteworthy biotech startups developing drugs that aim to increase lifespan include Retro Biosciences, which raised $180 million from OpenAI CEO Sam Altman two years ago and is reportedly raising a $1 billion Series A; and Altos Labs, which launched with $3 billion in 2022 and is backed by Jeff Bezos.
Topics
AI, Biotech & Health, brian armstrong, coinbase, drug discovery, NewLimit, Startups
Marina Temkin
Reporter, Venture
Marina Temkin is a venture capital and startups reporter at TechCrunch. Prior to joining TechCrunch, she wrote about VC for PitchBook and Venture Capital Journal. Earlier in her career, Marina was a financial analyst and earned a CFA charterholder designation.
View Bio
May 13, 2025
London, England
Get inside access to Europe’s top investment minds — with leaders from Monzo, Accel, Paladin Group, and more — plus top-tier networking at StrictlyVC London.
REGISTER NOW
Most Popular
Musk clashes with neighbors in exclusive Austin suburb
Connie Loizos
Is Duolingo the face of an AI jobs crisis?
Anthony Ha
Orb, a new app by Ookla’s ex-CEO, offers a broader picture of your internet connection
Ivan Mehta
Duolingo launches 148 courses created with AI after sharing plans to replace contractors with AI
Aisha Malik
Microsoft CEO says up to 30% of the company’s code was written by AI
Maxwell Zeff
Google launches AI tools for practicing languages through personalized lessons
Aisha Malik
Hugging Face releases a 3D-printed robotic arm starting at $100
Kyle Wiggers
Google debuts an updated Gemini 2.5 Pro AI model ahead of I/O do sex
Particle brings its AI-powered news reader to the web do sex
What OpenAI’s restructuring plan means for its corporate future do sex
